Planning, processing, research are the foundations on which we develop the four macro areas through which we elaborate our services
Development and application of models for economic and social burden analysis, budget impact analysis, and cost-effectiveness and cost-utility analysis.
Development of economic evaluations and pharmacoeconomic investigations in the national and international healthcare context in the perspective of a valuebased approach through the elaboration or adaptation of dynamic economic models.
Support for the elaboration of pricing and reimbursing dossier for the market authorization of health technologies in the italian setting.
Strategic support for the definition of Value Dossier at national, regional and local health authorities.
Development and evaluation of the impact of the integrated health pathway.
Bringing together different expertise for the development of integrated health pathway (PDTA, PCA, ...) elaborated at national level but adaptable to regional and local contexts in order to reduce variability in the management of patients.
Planning, organization and realization of scientific advisory boards and mock negotiations.
Involving of expert to combine the best available scientific evidence with the best clinical practices, taking into account the reference context and the different perspectives operating within the healthcare ecosystem.
Papers and Research
Altems Advisory develops valuable researches to face Companies, Institutions and non-profit organizations’ specific needs
Digital Medicine
Strumenti terapeutici innovativi per un cambio di paradigma nell’assistenza sanitaria digitale
Patient Access Network
Position Papers - I Edizione 2022/23
Budget impact of prophylactic treatment of rVIII-SingleChain in moderate and severe hemophilia A in Italy
Increasing the usage of rVIII-SingleChain for the prophylactic treatment of hemophilia A in Italy over 3 years may lead to cost savings with uncompromised efficacy in bleed protection, according to a budget impact analysis based on real-world data
Report HTA inebilizumab (NMOSD)
Analisi multidimensionale (HTA) di inebilizumab in pazienti con disturbi dello spettro della neuromielite ottica (NMOSD) sieropositivi per le immunoglobuline G anti-aquaporina-4 (IgG AQP4) in Italia
Budget impact of prophylactic treatment of rVIII-SingleChain in moderate and severe hemophilia A in Italy
Increasing the usage of rVIII-SingleChain for the prophylactic treatment of hemophilia A in Italy over 3 years may lead to cost savings with uncompromised efficacy in bleed protection, according to a budget impact analysis based on real-world data
Report HTA inebilizumab (NMOSD)
Analisi multidimensionale (HTA) di inebilizumab in pazienti con disturbi dello spettro della neuromielite ottica (NMOSD) sieropositivi per le immunoglobuline G anti-aquaporina-4 (IgG AQP4) in Italia
Report HTA inebilizumab (NMOSD)
Analisi multidimensionale (HTA) di inebilizumab in pazienti con disturbi dello spettro della neuromielite ottica (NMOSD) sieropositivi per le immunoglobuline G anti-aquaporina-4 (IgG AQP4) in Italia
Innovare la presa in carico della persona con Artrite Reumatoide: dagli unmet needs alla personalizzazione della cura
L'Artrite Reumatoide (AR) è una malattia infiammatoria cronica autoimmune che colpisce principalmente le articolazioni, causando danni strutturali e diverse comorbidità. In Italia, circa 400.000 persone soffrono di AR, con una prevalenza maggiore tra le donne di età compresa tra i 40 e i 60 anni. La gestione inefficace della malattia porta a significativi costi sanitari e sociali, accentuando la necessità di un approccio di cura personalizzato e integrato.